Truist notes that uniQure (QURE) has shared that based on recent pre-BLA mtg, the FDA is unlikely to approve AMT-130 with current data package. Based on the firm’s prior conversations with thought leaders in Huntington’s disease, this may, at least in part, be related to the use of ENROLL-HD natural history as matched control. This is a unique issue for uniQure with no read-throughs to PTC Therapeutics (PTCT) and Wave Life Sciences’ (WVE) HD programs, in Truit’s view.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure falls -50.2%
- Midday Fly By: AWS in deal with OpenAI, Kimberly-Clark to buy Kenvue
- FDA’s ‘surprising’ uniQure reversal drags down Biohaven
- Optimistic Buy Rating for uniQure Amid Promising AMT-130 Data and Regulatory Prospects
- FDA’s uniQure reversal unlikely to impact Regenxbio’s programs, says Stifel